19602-1-AP

antibody from Proteintech Group

Targeting: TRIP13 16E1BP

Provider product page for 19602-1-AP

Western blot

ELISA

Immunoprecipitation

Antibody data

Antibody Data
Antigen structure
References [29]
Comments [0]
Validations
Western blot [1]
Immunoprecipitation [1]

Submit

Product number: 19602-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#19602-1-AP, RRID:AB_10642702
Product name: TRIP13 antibody
Antibody type: Polyclonal
Description: KD/KO validated TRIP13 antibody (Cat. #19602-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IP, WB,ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

TRIP13 protein structure - 19602-1-AP shown in red.

Submitted references AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression.

Afaq F, Pathi SS, Chakravarthi BVSK, Chandrashekar DS, Carskadon S, Diffalha SA, Kunju LP, Palanisamy N, Manne U, Singh R, Varambally S
Translational oncology 2026 Jun;68:102743

TRIP13 promotes the expansion and immunosuppression of CD4(+)Foxp3(+) regulatory T cells by sustaining HAT1 stability.

He T, Zhao L, Feng CT, Zhao LY, Jing S, Yang H, Wang K, Ye S, Zhao Y, Yu Y, Fu Z, Chou CK, Chen X, Gao YJ
Cell death & disease 2026 Jan 14;17(1):32

Tetrahydrocurcumin targets TRIP13 inhibiting the interaction of TRIP13/USP7/c-FLIP to mediate c-FLIP ubiquitination in triple-negative breast cancer.

Sun YJ, Zhang Q, Cao SJ, Sun XH, Zhang JC, Zhang BY, Shang ZB, Zhao CY, Cao ZY, Zhang QJ, Gao XM, Qiu F, Kang N
Journal of advanced research 2025 Sep;75:591-605

Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis.

St Pierre L, Berhan A, Sung EK, Alvarez JR, Wang H, Ji Y, Liu Y, Yu H, Meier A, Afshar K, Golts EM, Lin GY, Castaldi A, Calvert BA, Ryan A, Zhou B, Offringa IA, Marconett CN, Borok Z
Biochimica et biophysica acta. Molecular basis of disease 2025 Mar;1871(3):167572

Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit.

Deng JH, Li HY, Liu ZY, Liang JP, Ren Y, Zeng YY, Wang YL, Mao XL
Acta pharmacologica Sinica 2025 Jun;46(6):1733-1741

Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.

Bunu SJ, Cai H, Zhou Z, Zhang Y, Lai Y, Wang G, Song D, Wu C, Zheng H, Xu Z, Shi J, Zhu W
RSC medicinal chemistry 2025 Jul 16;16(7):3132-3145

TRIP13 alters mitochondrial function and promotes bortezomib resistance in multiple myeloma.

Chen Y, Liu Y, Wang Y, Qi D, Peng C, Huang S, Guo J, Xu Z, Gu Y
Scientific reports 2025 Dec 6;16(1):1426

Mechanistic study of LINC01296 mediating TRIP13 regulation of neuroblastoma progression.

He Y, Fan J, Lin Y, Zheng C, Fang Y
Translational cancer research 2025 Dec 31;14(12):8418-8431

Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer.

Metousis A, Kenny HA, Shimizu A, Schweizer L, Ben-Moshe S, Bilecz A, Krishnan R, Zhang J, Alcazar I, Kelliher L, Ravi M, Samantaray T, Richter S, Li Y, Wang J, Steigerwald S, Theis FJ, Rosenberger FA, Nordmann TM, Yamada SD, Lastra R, Mann M, Lengyel E
medRxiv : the preprint server for health sciences 2025 Aug 28;

RTEL1 is upregulated in gastric cancer and promotes tumor growth.

Yang C, Wang S, Gao G, Xu P, Qian M, Yin Y, Yao S, Huang Z, Bian Z
Journal of cancer research and clinical oncology 2024 Dec 26;151(1):23

TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.

Chotiner JY, Leu NA, Yang F, Cossu IG, Guan Y, Lin H, Wang PJ
eLife 2024 Aug 29;12

TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21.

Zhang G, Yang R, Wang B, Yan Q, Zhao P, Zhang J, Su W, Yang L, Cui H
Cell death & disease 2024 Aug 26;15(8):622

ZFP541 and KCTD19 regulate chromatin organization and transcription programs for male meiotic progression.

Zhou X, Fang K, Liu Y, Li W, Tan Y, Zhang J, Yu X, Wang G, Zhang Y, Shang Y, Zhang L, Chen CD, Wang S
Cell proliferation 2024 Apr;57(4):e13567

An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.

Dhasmana S, Dhasmana A, Rios S, Enriquez-Perez IA, Khan S, Afaq F, Haque S, Manne U, Yallapu MM, Chauhan SC
Computational and structural biotechnology journal 2023;21:5765-5775

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.

Xiao Z, Li M, Zhang X, Rong X, Xu H
Oncology reports 2023 May;49(5)

KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.

Lu S, Liu Y, Tian S, He Y, Dong W
Experimental cell research 2023 May 1;426(1):113564

TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.

Chotiner JY, Leu NA, Yang F, Cossu IG, Guan Y, Lin H, Wang PJ
bioRxiv : the preprint server for biology 2023 Dec 15;

Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).

Bossuyt X, Vulsteke JB, Van Elslande J, Boon L, Wuyts G, Willebrords S, Frans G, Geukens N, Carpentier S, Tejpar S, Wildiers H, Blockmans D, De Langhe E, Vermeersch P, Derua R
Autoimmunity reviews 2023 Apr;22(4):103288

Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma.

Xu H, Ma Z, Mo X, Chen X, Xu F, Wu F, Chen H, Zhou G, Xia H, Zhang C
Journal of Cancer 2022;13(7):2226-2237

Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.

Rios Garcia M, Meissburger B, Chan J, de Guia RM, Mattijssen F, Roessler S, Birkenfeld AL, Raschzok N, Riols F, Tokarz J, Giroud M, Gil Lozano M, Hartleben G, Nawroth P, Haid M, López M, Herzig S, Berriel Diaz M
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022 Oct;9(29):e2104291

Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.

Lan J, Huang J, Tao X, Gao Y, Zhang L, Huang W, Luo J, Liu C, Deng Y, Liu L, Liu X
Journal of cellular and molecular medicine 2022 May;26(9):2673-2685

TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.

Li ZH, Lei L, Fei LR, Huang WJ, Zheng YW, Yang MQ, Wang Z, Liu CC, Xu HT
Journal of molecular histology 2021 Feb;52(1):11-20

SKP1 drives the prophase I to metaphase I transition during male meiosis.

Guan Y, Leu NA, Ma J, Chmátal L, Ruthel G, Bloom JC, Lampson MA, Schimenti JC, Luo M, Wang PJ
Science advances 2020 Mar;6(13):eaaz2129

TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.

Agarwal S, Behring M, Kim HG, Chandrashekar DS, Chakravarthi BVSK, Gupta N, Bajpai P, Elkholy A, Al Diffalha S, Datta PK, Heslin MJ, Varambally S, Manne U
Molecular oncology 2020 Dec;14(12):3007-3029

TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.

Di S, Li M, Ma Z, Guo K, Li X, Yan X
Pathology, research and practice 2019 Jun;215(6):152415

TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.

Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, Peng W, Wang X, Chen F, Cui H
British journal of cancer 2019 Dec;121(12):1069-1078

The PSMA8 subunit of the spermatoproteasome is essential for proper meiotic exit and mouse fertility.

Gómez-H L, Felipe-Medina N, Condezo YB, Garcia-Valiente R, Ramos I, Suja JA, Barbero JL, Roig I, Sánchez-Martín M, de Rooij DG, Llano E, Pendas AM
PLoS genetics 2019 Aug;15(8):e1008316

TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.

Sheng N, Yan L, Wu K, You W, Gong J, Hu L, Tan G, Chen H, Wang Z
Cell death & disease 2018 Mar 14;9(3):402

TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.

Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ
Nature communications 2014 Jul 31;5:4527

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Jurkat cells were subjected to SDS PAGE followed by western blot with 19602-1-AP(TRIP13 antibody) at dilution of 1:400
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The TRIP13 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human TRIP13. This antibody recognizes human,mouse,rat antigen. The TRIP13 antibody has been validated for the following applications: ELISA, WB, IP analysis.
Appendix: 19602-1-AP.pdf

: Show more